Skip to main content

Janus Henderson Investors — Portfolio, Page 9

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

227
Companies
$35.8B
Total invested
$153.6M
Avg. check
24
Industries
Biotechnology 21Health Care 12Therapeutics 11Life Science 8Medical 7Biopharma 5+18 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 193216 of 227
Ventyx Biosciences
September 2024

Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.

Biopharma · San Diego$27.0M Post Ipo Equity
Elektrofi
August 2024

Elektrofi develops hyper concentration microparticle technology for subcutaneous biologic medicine delivery.

Alternative Medicine · Boston$112.3M Series C
Inspirato
August 2024

Inspirato is a luxury travel and lifestyle subscription company.

Lifestyle · Denver$4.6M Post Ipo Equity
Day One Biopharmaceuticals
July 2024

Day One Biopharmaceuticals develops targeted therapies to treat people with life-threatening diseases.

Biopharma · South San Francisco$175.0M Post Ipo Equity
Scorpion Therapeutics
July 2024

Scorpion Therapeutics is a clinical-stage oncology company that specializes in precision medicine for cancer patients.

Biotechnology · Boston$150.0M Series C
Entrada Therapeutics
June 2024

Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.

Biotechnology · Boston$100.0M Post Ipo Equity
CARGO Therapeutics
May 2024

CARGO Therapeutics develops an adoptive cell therapy to benefit patients from potentially curative treatment options.

Biotechnology · San Mateo$110.0M Post Ipo Equity
P3 Health Partners
May 2024

P3 Health Partners is a patient-centered, physician-led and population health-focused healthcare company.

Finance · Henderson$42.2M Post Ipo Equity
Lycia Therapeutics
May 2024

Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.

Biotechnology · South San Francisco$106.6M Series C
Stoke Therapeutics
March 2024

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.

Biotechnology · Bedford$125.0M Post Ipo Equity
Akero Therapeutics
March 2024

Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.

Biotechnology · Cambridge$366.9M Post Ipo Equity
Applied Therapeutics
February 2024

Applied Therapeutics uses drug-development approach to target molecules and pathways that has roles in fatal or debilitating diseases.

Biotechnology · New York$100.0M Post Ipo Equity
ProfoundBio
February 2024

ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.

Biotechnology · Seattle$112.0M Series B
Attralus
February 2024

Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.

Biopharma · San Francisco$56.0M Series B
Tyra Biosciences
February 2024

Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.

Biotechnology · Carlsbad$200.0M Post Ipo Equity
Entact Bio
January 2024

Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function.

Biopharma · Watertown$40.3M Series Unknown
Verve Therapeutics
November 2023

Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.

Biotechnology · Boston$143.8M Post Ipo Equity
Gracell Biotechnologies
August 2023

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.

Biotechnology · Suzhou$100.0M Post Ipo Equity
Caribou Biosciences
July 2023

Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.

Biotechnology · Berkeley$125.0M Post Ipo Equity
TwinStrand Biosciences
June 2023

TwinStrand Biosciences develops and commercializes the duplex sequencing technology for DNA sequencing.

Biotechnology · Seattle$10.3M Series Unknown
IGM Biosciences
June 2023

IGM Biosciences is a biotechnology company that develops medicine for people with infectious infections, autoimmune diseases, and cancer.

Biotechnology · Mountain View$107.3M Post Ipo Equity
Elevation Oncology
June 2023

Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.

Biopharma · New York$50.0M Post Ipo Equity
Synthekine
January 2023

Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.

Biotechnology · Menlo Park$100.0M Series C
Loadsmart
September 2022

Loadsmart is a next-gen freight technology platform and 4PL that lower costs, increase efficiency, and digitize transportation for Shippers.

Logistics · ChicagoUndisclosed

Where Janus Henderson Investors invests

Biotechnology21
Health Care12
Therapeutics11
Life Science8
Medical7
Biopharma5

About Janus Henderson Investors's portfolio

How many companies has Janus Henderson Investors invested in?

Janus Henderson Investors has invested in 227 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Janus Henderson Investors invest in?

Janus Henderson Investors's top investment sectors include Biotechnology, Health Care, Therapeutics, Life Science, Medical. The firm invests across 24 different industry categories.

What is Janus Henderson Investors's largest investment?

Among tracked funding rounds, Akero Therapeutics received $366.9M in a Post Ipo Equity round. Janus Henderson Investors's total known invested capital is $35.8B.

What is the average investment size for Janus Henderson Investors?

Janus Henderson Investors's average investment size is $153.6M across its portfolio of 227 companies.

What are Janus Henderson Investors's most recent investments?

Recent Janus Henderson Investors portfolio additions include Ventyx Biosciences, Elektrofi, Inspirato, Day One Biopharmaceuticals, Scorpion Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 227 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →